Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era

Target-oriented agents improve metastatic colorectal cancer (mCRC) survival in combination with chemotherapy. However, the majority of patients experience disease progression after first-line treatment and are eligible for second-line approaches. In such a context, antiangiogenic and anti-Epidermal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Mol Sci
Hlavní autoři: Giordano, Guido, Parcesepe, Pietro, Bruno, Giuseppina, Piscazzi, Annamaria, Lizzi, Vincenzo, Remo, Andrea, Pancione, Massimo, D’Andrea, Mario Rosario, De Santis, Elena, Coppola, Luigi, Pietrafesa, Michele, Fersini, Alberto, Ambrosi, Antonio, Landriscina, Matteo
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2021
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8307359/
https://ncbi.nlm.nih.gov/pubmed/34299337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22147717
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky